World Hepatitis Day: The Role of Molecular Diagnostics and Precision Medicine in Advancing Hepatitis Care
What is Hepatitis?
Hepatitis is a condition characterized by inflammation of the liver, a vital organ responsible for essential functions including metabolism, detoxification, digestion, and nutrient processing. It can result from multiple causes, including viral infections, alcohol-related liver injury, certain medications, toxins, autoimmune diseases, and inherited genetic disorders (1).
Among these, viral hepatitis, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, represents a major global health challenge due to its association with chronic liver disease, cirrhosis, and hepatocellular carcinoma (2).
Observed annually on July 28, World Hepatitis Day aims to raise awareness about hepatitis prevention, promote timely diagnosis, and improve access to effective treatment. Early detection and appropriate clinical management are essential for reducing disease progression, preventing long-term liver complications, and improving patient outcomes.
Spectrum of Hepatitis: Types and Symptoms
Viral Hepatitis is caused by several hepatitis viruses, including hepatitis A, B, C, D, and E. Each type has distinct characteristics, modes of transmission, treatment approaches, and clinical outcomes. Hepatitis A and E usually cause acute infections, while hepatitis B, C, and D can develop into chronic infections associated with long-term liver complications (3,4,).
- Hepatitis A and E: Usually transmitted through contaminated food or water and commonly cause acute infections. Vaccination, good hygiene practices, and safe food handling help reduce transmission.
- Hepatitis B: Spread through infected blood and body fluids, including mother-to-child transmission, unsafe medical practices, and sexual contact. Chronic infection may lead to liver fibrosis, cirrhosis, and increased risk of liver cancer.
- Hepatitis C: Primarily transmitted through blood exposure. Many infections remain undiagnosed for years; however, advances in antiviral therapies have enabled successful treatment in most patients.
- Hepatitis D: Occurs only in individuals infected with hepatitis B and can accelerate liver damage and disease progression.
Symptoms may appear only after significant liver injury has developed; therefore, timely testing is essential for individuals at risk. Major symptoms may include, Fatigue and weakness, Loss of appetite, Nausea and vomiting, Abdominal discomfort, Fever, Dark-colored urine, Pale stools and jaundice (5).
Hepatitis Diagnosis: The Role of Molecular Diagnostics in Precision Healthcare
Molecular Testing: Molecular diagnostic techniques, including PCR-based assays, play a central role in hepatitis diagnosis and patient management. These methods directly detect viral genetic material (DNA or RNA) in patient samples, enabling confirmation of active infection, viral load quantification, and monitoring of treatment response. Unlike serological testing, which detect host antibodies or viral antigens, molecular diagnostic approaches provide direct evidence of viral infection. This allows earlier detection, accurate assessment of viral replication, and reliable monitoring during antiviral therapy (6).
Beyond routine diagnosis, targeted viral next-generation sequencing (NGS) can provide additional information in selected clinical and research settings. Viral NGS is different from human Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS), as it focuses specifically on viral genetic material.
Targeted viral NGS can support:
- Identification of viral genotypes and subtypes
- Detection of antiviral resistance-associated mutations
- Characterization of viral genetic variations relevant to surveillance and research
The Role of Genomics in Liver Disease and Precision Medicine
At DNA GTx, we support precision medicine through advanced molecular and genomic technologies.
It is important to clarify that Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are not diagnostic tests for viral hepatitis and cannot directly detect hepatitis viruses such as HBV or HCV.
However, these genomic technologies can provide valuable insights when liver disease is suspected to have an underlying genetic cause, including:
- Inherited liver disorders
- Unexplained chronic liver disease
- Genetic factors influencing disease susceptibility and progression
WES and WGS also contribute to research applications by improving our understanding of disease mechanisms, genetic variation, and factors that may influence treatment response and patient outcomes.
DNA GTx: Advancing Molecular Diagnostics and Precision Healthcare
Advances in molecular biology, genomics, and bioinformatics are transforming the understanding, diagnosis, and management of infectious diseases and complex disorders. At DNA GTx, we combine advanced sequencing technologies, molecular diagnostics, and bioinformatics expertise to support healthcare professionals and researchers in generating meaningful molecular insights.
Our solutions contribute to:
- Understanding genetic and molecular factors involved in disease progression
- Characterizing biological variations associated with health and disease
- Supporting research and innovation in infectious diseases and complex disorders
- Enabling precision healthcare approaches through advanced genomic analysis
By integrating technology with scientific expertise, DNA GTx is committed to advancing molecular diagnostics and precision medicine solutions that support improved disease understanding and informed clinical decision-making.
The Future of Hepatitis Care Through Precision Medicine
World Hepatitis Day highlights the importance of awareness, prevention, early detection, and effective treatment in reducing the global burden of hepatitis. Progress in vaccination, antiviral therapies, molecular diagnostics, and precision medicine have significantly improved the prevention, diagnosis, and management of hepatitis and liver diseases.
At DNA GTx, we are dedicated to leveraging molecular technologies, genomics and bioinformatics to support scientific innovation and contribute to the future of precision healthcare. Through advanced molecular solutions and research-driven approaches, DNA GTx continues to support improved disease understanding, accurate diagnostics, and better healthcare outcomes.
📚 References
- Guidotti, Luca G., and Francis V. Chisari. “Immunobiology and pathogenesis of viral hepatitis.” Rev. Pathol. Mech. Dis.1 (2006): 23-61.
- World Health Organization. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022–2030: report on progress and gaps 2024. World Health Organization, 2024.
- Fleurence, Rachael L., Harvey J. Alter, Francis S. Collins, and John W. Ward. “Global elimination of hepatitis C virus.” Annual Review of Medicine 76 (2025): 29-41. d
- European Association for the Study of the Liver. “EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.” Journal of hepatology 83, no. 2 (2025): 502-583.
- Patel, Sonal. “Hepatitis.” SA Pharmaceutical Journal82, no. 6 (2015): 20-23.
- Cobo, Fernando. “Application of molecular diagnostic techniques for viral testing.” The open virology journal6 (2012): 104.
Recent Blogs
Have a Question?
Have a specific question or request? Fill out the form below and our team will get back to you shortly.
